Time to BBVNA Relief
Temporal Trends and Predictors of Clinical Response Following Basivertebral Nerve (BVN) Ablation: A Prospective Observational Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Primary Objective:
• To determine the proportion of patients achieving clinical response (defined as ≥50% reduction in VAS or ≥15-point improvement in ODI) following BVNA.
Secondary Objectives:
- To assess changes in PROMIS-7, PAVS, and other patient-reported outcomes.
- To determine the incidence of further interventions such as epidural steroid injections (ESIs) or surgeries.
- To evaluate temporal trends in response and adverse events. A total of 11 visits inclusive of follow up visits with schedule for study intervals. 1 baseline visit, 8 virtual/ phone weekly visits, 1 3-month virtual visit , 1 6-month , 1 12-month and 1 24-month visit.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Charles A Odonkor, MD
- Phone Number: 203-767-1555
- Email: kcodonkor@aya.yale.edu
Study Contact Backup
- Name: Muhammad U Siddique, MD
- Phone Number: 203-668-2772
- Email: muhammad.siddique@yale.edu
Study Locations
-
-
Connecticut
-
Guilford, Connecticut, United States, 06437
- Recruiting
- Yale Spine and Pain Center - Guilford
-
New Haven, Connecticut, United States, 06519
- Recruiting
- Yale Pain Management Center - New Haven
-
Old Saybrook, Connecticut, United States, 06475
- Recruiting
- Yale Interventional Spine and Musculoskeletal Medicine - Old Saybrook
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of chronic axial low back pain with vertebrogenic features
- Scheduled for BVN ablation
- Able to provide informed consent
- Capable of participating in weekly virtual/telephone follow-up for 8 weeks and in- person or remote follow-up at 3 and 6 months through 2 years
Exclusion Criteria:
- Prior spinal neuromodulation therapy (e.g., spinal cord stimulation or intrathecal pump) within the past 6 months
- Active substance use disorder or uncontrolled psychiatric illness that may interfere with participation
- Cognitive impairment limiting ability to complete surveys or provide informed consent
- Pregnancy
- Incarceration or current status as a prisoner
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of participants achieving clinical response
Time Frame: 2 years
|
Clinical response defined as a ≥50% reduction in pain intensity from baseline as measured by the Visual Analog Scale (VAS) or a ≥15-point improvement in the Oswestry Disability Index (ODI) score
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of spine-related interventions
Time Frame: 2 years
|
Incidence of further spine-related interventions (e.g., epidural steroid injections, radiofrequency ablation, or spine surgery) post-BVN ablation.
|
2 years
|
|
Change in PROMIS-7 Global Health Score
Time Frame: 2 years
|
7-item, self-report, or parent-proxy tool designed to assess overall physical, mental, and social health using a 5-point Likert scale., score range 20-80.
It generates a T-score, where 50 is the U.S. population average and 10 is the standard deviation.
Higher scores indicate better overall health.
|
2 years
|
|
Percentage of participants with incresed physical activity assessed using Physical Activity Vital Sign (PAVS)
Time Frame: 2 years
|
2-question screening tool used in clinical settings to assess if adults meet the recommended 150+ minutes of weekly moderate-to-vigorous physical activity.
Calculate the total weekly minutes of exercise by multiplying #1 times #2.
|
2 years
|
|
Patient Global Impression of Change (PGIC) score
Time Frame: 2 years
|
Self-report 7-point scale measuring a patient's belief regarding the effectiveness of a treatment with higher scores indicating a better outcome.
Score range 1-7.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Charles A Odonkor, MD, Yale University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2000040858
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.